Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease
Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was generally safe and well tolerated in all dose groups, demonstrating a favorable PK profile in validating gut-restrictive properties. Supported by Insilico's...
Tech Trends That WON'T Happen in 2025: AI-RAN, Consumer Smart Glasses, Humanoids, and Semiconductor Onshoring - To Name a Few
ABI Research's 5th annual Trend Report identifies the 53 key technology trends that will come to fruition—and the 48 that won't—in 2025 NEW YORK, Dec. 12, 2024 /PRNewswire/ -- As 2025 kicks off, predictions abound on the technology innovations...